To find that new drug, codenamed “LIFE-001,” LifeMine looked to a billion-year-old place: the fungal genome. Through its discovery work, LifeMine has come up with a compound, LIFE-001, that instead directly inhibits calcineurin by binding to a site that wasn’t previously seen in the enzyme’s structure. Data in islet transplant recipients could come by the end of 2027, while results from the kidney transplant study are expected in 2028. Formed in 2017, LifeMine is one of many drug startups co-founded by Verdine, a former Harvard University chemical biologist. About $75 million of that total came from a Series D financing LifeMine raised in the fourth quarter of 2025.